{
    "project_id": "171589",
    "broad_study_type": "other",
    "narrow_study_type": "mechanistic_study",
    "trial_phase": "N/A",
    "observational_timeframe": "N/A",
    "justification": "In this proposal, we plan to further delineate the mechanisms underlying the actions of GnRH-II and gonadotropins in epithelial ovarian cancer cells, with emphasis on cell invasiveness. In particular, we will examine the cross-talk between these hormones and epidermal growth factor (EGF) that is known to play key roles in ovarian cancer cell progression.",
    "data_type": "canadian",
    "ipd_used": "individual",
    "novelty_statement": "The findings will add significantly to our understanding of the invasive properties of epithelial ovarian carcinomas, which are responsible for most of the morbidity and mortality due to ovarian cancer.",
    "replication_study": "no",
    "target_population_size": "N/A",
    "age_range": "unclear",
    "gender_focus": "female",
    "vulnerable_populations": "no",
    "rare_disease": "no",
    "population_description": "epithelial ovarian cancer cells",
    "intervention_category": "N/A",
    "intervention_name": "N/A",
    "control_type": "experimental_control",
    "dose_response": "unclear",
    "combination_therapy": "no",
    "personalized_medicine": "no",
    "primary_outcome": "endocrine influences on epithelial ovarian cancer",
    "primary_outcome_type": "biomarker",
    "safety_focus": "no",
    "quality_of_life": "no",
    "biomarker_endpoints": "yes",
    "time_to_event": "no",
    "composite_endpoint": "no",
    "ai_machine_learning": "no",
    "digital_health": "no",
    "telemedicine": "no",
    "wearable_technology": "no",
    "big_data_analytics": "no",
    "blockchain": "no",
    "cost_effectiveness": "no",
    "budget_impact": "no",
    "health_technology_assessment": "no",
    "resource_utilization": "no",
    "productivity_outcomes": "no",
    "implementation_science": "no",
    "policy_evaluation": "no",
    "health_system_integration": "no",
    "scalability_assessment": "no",
    "barrier_identification": "no",
    "adaptive_design": "no",
    "bayesian_methods": "no",
    "machine_learning_analysis": "no",
    "novel_biostatistics": "no",
    "patient_reported_outcomes": "no",
    "real_world_evidence": "no",
    "industry_partnership": "no",
    "patient_engagement": "no",
    "community_based": "no",
    "indigenous_collaboration": "no",
    "international_collaboration": "no",
    "international_network": "no",
    "regulatory_pathway": "no",
    "ethics_focus": "no",
    "consent_innovation": "no",
    "data_sharing": "no",
    "therapeutic_area": "cancer",
    "disease_stage": "unclear",
    "comorbidity_focus": "no",
    "pandemic_related": "no",
    "environmental_health": "no",
    "social_determinants": "no",
    "health_equity": "no",
    "climate_health": "no",
    "urban_rural": "unclear",
    "biobank_use": "no",
    "registry_linkage": "no",
    "cohort_establishment": "no",
    "platform_trial": "no",
    "study_duration": "long_term",
    "multicenter": "no",
    "healthcare_setting": "laboratory",
    "disease_area": "ovarian cancer",
    "methodology_innovation": "delineating the mechanisms of GnRH-II and gonadotropins in epithelial ovarian cancer cell invasiveness, and their cross-talk with EGF",
    "knowledge_translation_focus": "yes",
    "equity_considerations": "no"
} 